A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...

A creatine kinase test is a blood test that measures levels of an enzyme called creatine kinase. This enzyme supports energy production in the body and is particularly important for muscle and ...

p27 (also known as KIP1, and encoded by CDKN1B) is regulated by multiple signal transduction pathways in normal and malignant cells. CDKN1B transcription can be regulated by the FoxO family and ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...

Cholinesterase inhibitors prevent the breakdown of a type of neurotransmitter called acetylcholine. Doctors may prescribe this medication for certain neurodegenerative diseases, such as Alzheimer ...

Shanghai Engineering Research Center of Molecular Therapeutics & New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China ...

About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells ...

The modification of the ribosomal tunnel is conceptually similar to macrocycle-based modification of a protein–protein interaction surface. It is distinct from the enzymatic reaction inhibition ...